Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Thursday, December 13, 2018 · 471,072,170 Articles · 3+ Million Readers

MEDIA ADVISORY -- Dr. Heinrich Roder, Biodesix CTO, To Speak At Precision Medicine World Conference

ADVISORY, Jan. 19, 2018 (GLOBE NEWSWIRE) --

WHAT: Dr. Heinrich Roder, Biodesix’ CTO, will speak on “Applied Machine Learning for Immuno-Oncology Diagnostics” in the “AI and Data Science Showcase” track at the Precision Medicine World Conference (PMWC) in Mountain View, CA.

WHO: Heinrich Roder is a company founder and author or co-author of more than 100 publications and talks spanning the fields of theoretical physics, computational sciences, and molecular diagnostics. A Rhodes Scholar, he earned his DPhil in Theoretical Physics from the University of Oxford and has held positions at the Universities of Hanover and Bayreuth and at Los Alamos National Laboratory. He is a founder of Biodesix. Serving as CTO, he leads the work of the Research and Development team on sensitive, high-throughput MALDI-ToF mass spectrometry profiling of blood-based samples. His team develops molecular diagnostic tests using a proprietary analytics platform based on machine learning.

WHEN/WHERE: Monday, January 22nd, 10:30AM PST, at the Computer History Museum, 1401 N. Shoreline Blvd, Mountain View, CA.

About Biodesix
Biodesix® is a molecular diagnostics company advancing the development of innovative blood tests in oncology to enable precision medicine. Biodesix discovers, develops and commercializes multivariate protein and genomic diagnostic blood tests, including the GeneStrat® and VeriStrat® tests, that deliver results within 72 hours. The company is changing the standard of care by providing physicians with diagnostic tests for better therapeutic guidance, more accurate prognosis and enhanced disease monitoring to improve patient outcomes. At the forefront of precision medicine, Biodesix is developing new blood tests to identify patients who may benefit from immunotherapies. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics for use with therapeutic agents. 

For more information about Biodesix, please visit www.Biodesix.com.

Contact: Rachel Biederman
720-214-5774
rachel.biederman@biodesix.com

/EIN News/ -- Primary Logo

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release